肾臟病诊断市场规模、份额和成长分析（按检测类型、产品、最终用户和地区划分）—产业预测，2026-2033年

预计到 2024 年，肾臟病诊断市场规模将达到 11.2 亿美元，到 2025 年将达到 11.5 亿美元，到 2033 年将达到 14.7 亿美元，在预测期（2026-2033 年）内，复合年增长率为 3.1%。

由于人们对孕产妇健康和妊娠併发症的认识不断提高，全球肾臟病诊断市场正经历显着成长。妊娠毒血症是一种影响产科的高血压疾病，它推动了对精准早期诊断技术的需求，促使主要企业在该领域进行创新。医疗保健支出不断增长、新兴市场医疗基础设施不断完善以及产科护理中先进医疗技术的应用等因素，进一步推动了市场扩张。然而，先进诊断技术的高成本以及某些地区优质医疗资源的匮乏等挑战，可能会阻碍市场发展。对新型生物标记和非侵入性诊断策略的持续研究，预计将进一步推动肾臟病诊断市场的发展。

肾臟病诊断市场驱动因素

肾臟病诊断市场的发展动力源自于准确诊断孕妇子痫前症的复杂性。仅凭血压升高并不能确诊，凸显了提高公众意识的重要性。遗憾的是，许多女性对妊娠毒血症及其相关风险缺乏足够的了解，导致孕期高血压的识别延迟。这种认知不足限制了及时介入的可能性，因为疾病往往在症状恶化之前难以察觉。由此对母亲和新生儿带来的健康风险十分严重，并导致婴儿死亡率上升，因此迫切需要改进诊断方案。

限制肾臟病诊断市场的因素

由于妊娠高血压疾病的诊断难度较高，仅凭血压升高并不能确诊，因此肾臟病诊断市场面临严峻的挑战。此外，许多孕妇缺乏对妊娠毒血症的认识，不了解其影响和相关风险。妊娠高血压往往在出现更严重的症状之前难以被发现，这限制了及时介入的机会。对妊娠毒血症的征兆和潜在併发症缺乏了解，不仅会严重危害母亲的健康，还会增加婴儿上行风险，这成为市场成长的一大障碍。

肾臟病诊断市场趋势

全球肾臟病诊断市场的一个显着趋势是，对孕妇早期风险评估的重视程度日益提高。这项转变推动了基于生物标记的检测方法的应用，这些方法利用与妊娠毒血症相关的特定生物标记。这些检测能够及时识别潜在病例，使医护人员能够实施早期疗育并改善管理策略，最终改善母婴结果。随着医疗系统日益重视孕产妇健康和预防保健，先进诊断工具的整合体现了其致力于最大限度减少妊娠毒血症对妊娠结局不良影响的决心。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步

全球肾臟病诊断市场规模（按检测类型划分）、复合年增长率（2026-2033 年）

• 血液检查
• 尿液检查
• 其他的

全球肾臟病诊断市场规模（按产品划分）、复合年增长率（2026-2033 年）

• 装置
• 消耗品

全球肾臟病诊断市场规模（按最终用户划分）、复合年增长率（2026-2033 年）

• 医院
• 专科诊所
• 诊断中心
• 其他的

全球肾臟病诊断市场规模（按地区划分）、复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Diabetomics Inc.（United States）
• DRG Instruments GmbH（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• PerkinElmer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific（United States）
• GE Healthcare（United States）
• Abbott Laboratories（United States）
• Acon Laboratories, Inc.（United States）
• Arkray, Inc.（Japan）
• Bio-Rad Laboratories, Inc.（United States）
• Cardinal Health（United States）
• Danaher Corporation（Beckman Coulter, Inc.）（United States）
• DIRUI Industrial Co., Ltd.（China）
• Metabolomic Diagnostics Ltd.（Ireland）
• Sera Prognostics（United States）
• Synlab Group（Germany）
• Microlife Corporation（Switzerland）
• Bayer AG（Germany）
• Progenity Inc.（United States）

结论与建议

Preeclampsia Diagnostics Market size was valued at USD 1.12 Billion in 2024 and is poised to grow from USD 1.15 Billion in 2025 to USD 1.47 Billion by 2033, growing at a CAGR of 3.1% during the forecast period (2026-2033).

The global market for preeclampsia diagnostics is experiencing significant growth driven by heightened awareness of maternal health and pregnancy complications. Preeclampsia, a hypertensive disorder impacting obstetrics, has spurred demand for precise and early diagnostic techniques, encouraging key players to innovate in this space. Factors such as increasing healthcare spending, enhancements in healthcare infrastructure in emerging markets, and the adoption of advanced medical technologies in obstetric care further bolster market expansion. Nonetheless, challenges like the high costs of sophisticated diagnostic methods and limited access to quality healthcare in specific regions could impede progress. Ongoing research into novel biomarkers and non-invasive diagnostic strategies is poised to propel the preeclampsia diagnostics market toward further advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preeclampsia Diagnostics Market Segments Analysis

Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market is driven by the complexities involved in accurately diagnosing this condition in expectant mothers. A mere spike in blood pressure does not provide a definitive diagnosis, which makes awareness crucial. Unfortunately, many women remain uninformed about preeclampsia and its associated risks, leading to a delay in recognizing hypertension during pregnancy. As symptoms often go unnoticed until they escalate, this gap in understanding limits the potential for timely intervention. The resulting health risks for mothers and their newborns can have severe consequences, contributing to higher rates of infant mortality and underscoring the urgent need for improved diagnostic solutions.

Restraints in the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market faces significant challenges due to the complexity of accurately diagnosing this condition in pregnant women, as a mere rise in blood pressure does not provide definitive results. Additionally, a substantial number of pregnant individuals lack awareness about preeclampsia, its implications, and associated risks. Often, hypertension during pregnancy remains undetected until more severe symptoms develop, which restricts timely intervention opportunities. This gap in knowledge regarding the signs and potential complications of preeclampsia not only poses serious health risks to mothers but also increases the likelihood of higher infant mortality rates, presenting a critical barrier to market growth.

Market Trends of the Preeclampsia Diagnostics Market

The global preeclampsia diagnostics market is witnessing a noteworthy trend characterized by an enhanced focus on early risk assessment for expectant mothers. This shift is propelling the adoption of biomarker-based testing methods, which harness specific biological markers linked to preeclampsia. By facilitating the timely identification of potential cases, these tests empower healthcare professionals to administer early interventions and improve management strategies, ultimately fostering better outcomes for both mothers and their babies. As healthcare systems increasingly prioritize maternal health and preventative care, the integration of advanced diagnostic tools reflects a commitment to minimizing the adverse effects of preeclampsia on pregnancy outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Urine Analysis
• Others

Global Preeclampsia Diagnostics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
• Consumables

Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

Global Preeclampsia Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Product, End-user)
  • US
  • Canada
• Europe (Test Type, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Diabetomics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DRG Instruments GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkray, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DIRUI Industrial Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Diagnostics Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sera Prognostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlab Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microlife Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations